| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.20▼ | 0.21▼ | 0.21▼ | 0.20▲ | 0.25▼ |
| MA10 | 0.21▼ | 0.21▼ | 0.21▼ | 0.21▼ | 0.38▼ |
| MA20 | 0.21▼ | 0.21▼ | 0.20▼ | 0.25▼ | 0.83▼ |
| MA50 | 0.21▼ | 0.21▼ | 0.22▼ | 0.46▼ | 1.52▼ |
| MA100 | 0.21▼ | 0.24▼ | 0.26▼ | 0.89▼ | 8.54▼ |
| MA200 | 0.24▼ | 0.27▼ | 0.29▼ | 1.24▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | 0.000▼ | 0.001▲ | 0.012▲ | 0.007▲ |
| RSI | 40.872▼ | 43.435▼ | 43.201▼ | 28.120▼ | 24.510▼ |
| STOCH | 0.333▼ | 26.153 | 48.193 | 12.762▼ | 1.758▼ |
| WILL %R | -98.913▼ | -81.250▼ | -50.696 | -87.547▼ | -98.643▼ |
| CCI | -88.734 | -89.885 | -19.708 | -64.887 | -71.551 |
|
Tuesday, March 31, 2026 06:12 AM
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian ...
|
|
Saturday, March 21, 2026 09:38 AM
Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.
|
|
Friday, February 20, 2026 06:06 AM
CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/04/26 | 0.202 | 0.2087 | 0.1963 | 0.2005 | 194,821 |
| 01/04/26 | 0.2053 | 0.225 | 0.1985 | 0.2105 | 596,940 |
| 31/03/26 | 0.1945 | 0.205 | 0.1872 | 0.199 | 835,872 |
| 30/03/26 | 0.2005 | 0.2006 | 0.184 | 0.189 | 550,530 |
| 27/03/26 | 0.2106 | 0.2106 | 0.202 | 0.202 | 196,948 |
| 26/03/26 | 0.207 | 0.2194 | 0.2022 | 0.2082 | 394,722 |
| 25/03/26 | 0.21 | 0.22 | 0.20 | 0.21 | 726,700 |
| 24/03/26 | 0.2339 | 0.2339 | 0.2087 | 0.2118 | 775,792 |
| 23/03/26 | 0.255 | 0.255 | 0.2116 | 0.235 | 2,935,034 |
| 20/03/26 | 0.279 | 0.285 | 0.2564 | 0.2657 | 1,582,113 |
|
|
||||
|
|
||||
|
|